arrow
H

Han Chu Lee

University of Ulsan College of Medicine
H指数:64
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma

Child-Pugh B肝细胞癌患者对阿替利珠单抗-贝伐珠单抗反应的临床预测因子

2026-06-110
OAAI
Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol

多中心前瞻性试验:比较使用钆塞酸缩短扫描时间的MRI与CT对晚期复发性肝癌的检测(AMRICT研究方案)

2026-04-240
OA
Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score-Weighted Analysis

联合经动脉化疗栓塞与外照射放疗用于筛选伴有大血管侵犯的肝细胞癌手术候选者:一项倾向性评分加权分析

2026-01-011
OAAI
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

“A-B-C”分类揭示了atezolizumab/bevacizumab治疗下肝细胞癌患者的结局轨迹

2025-11-250
OAAI
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Regorafenib联合nivolumab治疗不可切除的肝细胞癌: 2期RENOBATE试验

2024-02-1914
OAAI